David Ambinder, MD
David Ambinder, MD, is a urology resident at New York Medical College/Westchester Medical Center. His interests include surgical education, GU oncology, and advancements in technology in urology. A significant portion of his research has been focused on litigation in urology.
Articles by David Ambinder, MD
Dr. Yerram elucidates the evolving landscape of focal therapy for prostate cancer, emphasizing its ease of adoption.
Dr. Yerram describes his post-HIFU surveillance protocol: regular PSA checks, MRI, and biopsies at defined intervals.
Dr. Yerram explains the use of HIFU and cryotherapy as primary focal therapy modalities, emphasizing a few treatment options.
Dr. Yerram explains how advances in focal therapy technologies over the past decade have driven increased use and acceptance.
Dr. Ghazi is recognized as a pioneer in patient-specific surgical simulation, using state-of-the-art techniques in surgery.
Dr. Ghazi concludes with the reception of his surgical simulation models, highlighting the challenges and successes.
Dr. Ghazi emphasizes the need for simulation platforms that replicate real surgery experiences more accurately than cadavers.
Dr. Ghazi discusses the evolution to laparoscopic and robotic techniques, highlighting the need for structured simulation.
Drs. Stifelman and Ambinder discuss the novel approaches and adoption challenges of single-port and Da Vinci 5 systems.
Drs. Ambinder and Sonpavde provide an update for CheckMate 901, characterizing treatment benefit in responders.
Drs. Ambinder and Elsamra explore robotic surgery, including its applicability, patient benefits, and evolving role.
Approximately 40 clinical trials related to bladder cancer were published at the end of 2022 and throughout 2023.
Enzalutamide plus leuprolide and enzalutamide monotherapy resulted in significantly MFS and a longer time to PSA progression.
The SUO meeting pays special attention to patients who responded well to NAC, the BCG shortage, trimodal therapy, and more.
Is there a better way to manage low-grade NMIBC? Adding UGN-102 to the current standard of care may be the answer.
From presentation with a testicular mass to treatment options, this provides valuable insights for community oncologists.
Drs. Bagrodia and Ambinder provide an overview of the care continuum for newly diagnosed testicular cancer patients.
Drs. Bagrodia and Ambinder walk through a community urologist's approach to a patient who presents with a testicular mass.
A recent study adds to the scant literature on preclinical bladder autotransplantation before a first-in-human trial.
Unique characteristics include higher stage at presentation and a more aggressive subsequent clinical course.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.